Oculis CEO Outlines Phase 3 PIONEER Program

Clinical Report: Oculis CEO Outlines Phase 3 PIONEER Program

Overview

At the 2026 American Academy of Ophthalmology meeting, Oculis CEO Riad Sherif, MD, described the Phase 3 PIONEER program evaluating investigational neuroprotective therapy privosegtor (OCS-05) for optic neuritis. Sherif cited Phase 2 ACUITY findings and said PIONEER-1 had begun enrolling patients, with PIONEER-2 starting and PIONEER-3 planned to follow.

Background

Optic neuritis is an acute optic neuropathy for which treatment approaches and outcomes vary by underlying disease phenotype. Consensus guidance cited in the supplied background recommends high-dose intravenous methylprednisolone for adults with acute optic neuritis and consideration of plasma exchange or intravenous immunoglobulin when vision does not improve after steroids. The supplied background also notes that acute nonarteritic anterior ischemic optic neuropathy has no universally accepted treatment reliably shown to improve visual outcomes. Privosegtor is being developed as a neuroprotective candidate for optic neuritis and nonarteritic anterior ischemic optic neuropathy.

Data Highlights

Program or study	Population or indication	Reported status or finding
Phase 2 ACUITY	Patients treated with privosegtor plus steroids versus steroids alone, as described by Sherif	Sherif reported an 18-letter greater vision improvement with privosegtor, preservation or improvement of retinal anatomy, and reduced neurofilament release. The supplied transcript does not provide study methods or statistical estimates.
PIONEER-1	Optic neuritis; related coverage describes acute-onset optic neuritis, including patients with and without multiple sclerosis	Sherif said the Phase 3 trial had started and patients were being randomized. Related coverage reports that the first patient was treated and that the trial assesses visual outcomes at month 3.
PIONEER-2	Not specified in the supplied transcript	Sherif said the study was starting.
PIONEER-3	Not specified in the supplied transcript	Sherif said the study would start after PIONEER-2.

Key Findings

Sherif characterized privosegtor (OCS-05) as an investigational neuroprotective candidate and cited its development for optic neuritis and nonarteritic anterior ischemic optic neuropathy.
According to Sherif, Phase 2 ACUITY showed an 18-letter greater vision improvement with privosegtor compared with steroids alone.
Sherif also reported preservation or improvement of retinal anatomy through preservation of retinal ganglion cells and reduced neurofilament release, which he described as indicating less axonal damage.
Sherif said PIONEER-1, a Phase 3 study in optic neuritis, had begun and was randomizing patients. Related coverage reports that it is enrolling patients with acute-onset optic neuritis, with and without multiple sclerosis, and evaluates visual outcomes at month 3.
The supplied related coverage reports FDA agreement on the PIONEER-1 study design and planned statistical analysis through a special protocol assessment.
Sherif described PIONEER-2 as starting and PIONEER-3 as planned to start afterward; the transcript does not specify their populations or endpoints.

Clinical Implications

The supplied material describes privosegtor as investigational and does not report Phase 3 efficacy or safety outcomes. The PIONEER program is evaluating the candidate in optic neuritis; the transcript does not provide clinical-use recommendations or establish a role in current treatment.

Conclusion

Oculis is advancing privosegtor through a planned three-study Phase 3 program, beginning with PIONEER-1 in optic neuritis. The efficacy statements in the interview refer to Phase 2 ACUITY, while confirmatory Phase 3 results are not provided in the supplied material.